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AbsTrACT
Public health interventions and health technologies 
are commonly described as ‘complex’, as they involve 
multiple interacting components and outcomes, and their 
effects are largely influenced by contextual interactions 
and system-level processes. Systematic reviewers and 
guideline developers evaluating the effects of these 
complex interventions and technologies report difficulties 
in using existing methods and frameworks, such as the 
Grading of Recommendations Assessment, Development 
and Evaluation (GRADE). As part of a special series 
of papers on implications of complexity in the WHO 
guideline development, this paper serves as a primer on 
how to consider sources of complexity when using the 
GRADE approach to rate certainty of evidence. Relevant 
sources of complexity in systematic reviews, health 
technology assessments and guidelines of public health 
are outlined and mapped onto the reported difficulties in 
rating the estimates of the effect of these interventions. 
Recommendations on how to address these difficulties 
are further outlined, and the need for an integrated use 
of GRADE from the beginning of the review or guideline 
development is emphasised. The content of this paper 
is informed by the existing GRADE guidance, an ongoing 
research project on considering sources of complexity 
when applying the GRADE approach to rate certainty of 
evidence in systematic reviews and the review authors’ 
own experiences with using GRADE.
InTroduCTIon
systematic reviews on the effects of 
interventions in global health
Systematic reviews that estimate the effects 
of interventions can have a significant influ-
ence on subsequent decisions to either 
implement or disinvest in an intervention. In 
biomedicine, there are established methods 
for synthesising and rating certainty in the 
effects of medications and other single-com-
ponent interventions.1 Researchers in public 
health and health technology assessment 
(HTA) report difficulties in using these 
methods,2 3 largely stemming from failure 
to account for ‘what interventions work, for 
whom, and under what circumstances’,4 to 
further inform development of context-spe-
cific recommendations.5 6 
Key questions
What is already known?
 ► The Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach is an 
internationally prominent system for rating certainty 
of the evidence in systematic reviews estimating in-
tervention effects.
 ► Researchers conducting systematic reviews on pub-
lic health and health system interventions report dif-
ficulties in using the GRADE approach.
What are the new findings?
 ► Applying a ‘complexity perspective’ can help identify 
aspects of using the GRADE approach that require 
particular consideration when rating certainty in the 
estimates from systematic reviews estimating the 
effects of global health interventions.
 ► These aspects include: sources of complexity when 
framing the review questions, such as important di-
mensions of context and implementation and oth-
er potential mediators and moderators of effect; a 
choice of thresholds or ranges for certainty of evi-
dence ratings that matches the needs of intended 
users of the review; assessment of evidence from 
non-randomised study designs; the criteria within 
each GRADE domain for rating certainty of evidence 
and coherence of evidence across the hypothesised 
causal pathway of the intervention.
What do the new findings imply?
 ► This primer can help systematic reviewers, health 
technology assessors and guideline developers 
better assess evidence relating to complex interven-
tions and systems, which could enhance the use of 
such evidence in global health policy and practice 
decisions.
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WHO is the leading institution for producing 
evidence-informed guidelines at a global level. WHO 
recommendations for practice and policy are under-
pinned by systematic reviews of evidence on the effects 
of interventions and health technologies and aim to 
follow a transparent and evidence-based process.7 
Review and HTAs that inform recommendations 
often need to consider a range of populations, inter-
ventions with different implementation strategies, 
multiple health and non-health outcomes and various 
contextual factors that may interact and modify inter-
vention effects.8 Given the pressing needs and limited 
resources in low-income and middle-income countries 
(LMICs), appropriate application of evidence synthesis 
on a broad range of health interventions is crucial for 
optimal decisions about implementation.9
using a complexity perspective in reviews of intervention 
effects
Recently, there has been increased attention to evaluating 
effects of complex health interventions implemented 
within complex systems.10 This complexity creates chal-
lenges for guideline development and HTAs, from the 
conceptualisation of the questions asked to synthesising 
diverse types of evidence, assessing or rating the evidence 
and formulating recommendations. This paper is one 
of a series exploring the implications of complexity for 
systematic reviews, HTAs and guideline development.
Using a complexity perspective in systematic reviews 
of the effects of interventions can facilitate the more 
nuanced conceptualisation and assessment of interven-
tions ultimately needed for health decision making.11 
An earlier paper in this series differentiates between 
two main perspectives on sources of complexity in the 
evaluation of interventions.10 A ‘complex interventions 
perspective’ locates sources of complexity in the features 
of interventions themselves, such as interventions with 
different components addressing different and multiple 
causes of problems.12 A ‘complex systems perspective’, 
on the other hand, locates sources of complexity in the 
properties of systems into which interventions are intro-
duced, such as how the intervention interacts with, and 
impacts on, the system as a whole.13 We use the overar-
ching term ‘complexity perspective’ to encompass both 
perspectives and acknowledge the many sources of 
complexity.10 Depending on the priority questions of a 
review, an HTA, or a guideline, either perspective or a 
combination may be adopted.
In planning and undertaking systematic reviews, a 
‘complex systems perspective’ necessarily entails broad-
ening the scope of a review to include evidence on how 
the wider system changes when the intervention, such as 
a complex technology, is introduced. This may involve 
collecting qualitative evidence on social norms and the 
dynamics of social networks to describe the broader 
system impact of the intervention. Not all sources of 
complexity are relevant to every systematic review and 
HTA. Researchers should take a pragmatic approach 
that focuses on the key aspects of interventions, their 
causal pathways and the levels of target relevant to the 
specific aims of the review and users’ needs. There is 
a growing body of literature and guidance, which can 
be helpful in deciding on the important sources of 
complexity to consider in systematic reviews, HTAs and 
guidelines, including approaches described in earlier 
papers in this series, by Booth et al,14 Petticrew et al10 
and Rehfuess et al15 (see box 1).
The GrAdE approach to rating certainty of evidence
The GRADE Working Group has taken a leading role 
in developing guidance and methods for using research 
evidence to inform healthcare recommendations. 
Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) offers an explicit and trans-
parent system for rating certainty in the body of evidence 
underpinning conclusions in a systematic review, an HTA 
or a guideline (box 2). In GRADE, certainty of the effect 
box 1 Examples of guidance and tools for addressing 
sources of complexity
 ► Context and Implementation of Complex Interventions framework63
 ► Guidance on the integrated assessment of complex health technol-
ogies: the INTEGRATE-HTA model64
 ► Intervention Complexity Assessment Tool for Systematic Reviews65
 ► Preferred Reporting Items for Complex Interventions for Systematic 
Reviews and Meta-analyses66
 ► Template for Intervention Description and Replication tool6 67
box 2 summary of the GrAdE process for rating the 
certainty of evidence for intervention effects
 ► The Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) process starts with an initial certainty rating 
based on the design of studies included in the body of evidence: 
if the body of evidence contributing to an outcome consists of 
randomised controlled trials, certainty is initially rated as ‘high’, 
whereas a body of evidence consisting of observational or non-ran-
domised studies (NRSs) is initially rated as ‘low’.
 ► The assessing team then uses five domains for potential down-
grading of the initial certainty rating: study limitations, indirectness, 
inconsistency, imprecision and publication bias.
 ► Next, the team assesses three further domains for potential up-
grading of the initial certainty rating: magnitude of the effect, 
dose–response relationship in the effect and counteracting plau-
sible residual bias or confounding.43 These upgrading domains are 
primarily relevant to NRSs (eg, cohort, before–after and interrupted 
time series).
 ► Evidence Profiles and Summary of Findings tables are used to sum-
marise the effect estimates and the certainty ratings for those esti-
mates for each main outcome in the assessment.
 ► The GRADE ratings are further used as one of the criteria in the 
Evidence to Decision frameworks to inform recommendations 
about implementing interventions in practice, where high-certainty 
evidence is more likely to result in a strong recommendation com-
pared with low-certainty evidence.68
 o
n
 25 February 2019 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2018-000848 on 25 January 2019. Downloaded from 
Montgomery P, et al. BMJ Glob Health 2019;4:e000848. doi:10.1136/bmjgh-2018-000848 3
BMJ Global Health
estimate for each outcome is ultimately assigned one of 
four categories: high, moderate, low or very low. The 
GRADE approach has been widely adopted by system-
atic reviewers, authors of HTA and guideline developers 
in healthcare, including over 100 organisations world-
wide.16 Among these, WHO uses GRADE to inform global 
health recommendations,16 and the Cochrane Collabora-
tion mandates use of GRADE in Cochrane intervention 
reviews.17
Despite its wide uptake in biomedicine, systematic 
reviewers and guideline developers report difficulties 
applying GRADE in reviews of broader health tech-
nologies, health system and public health interven-
tions.2 3 These challenges are frequently attributed to the 
complexity of these interventions, often requiring sophis-
ticated consideration and analysis.3 13 For example, high 
levels and various sources of heterogeneity in reviews of 
public health interventions often lead to challenges in 
deciding how and whether to downgrade for inconsis-
tency.3 18 Another common challenge results from the 
difficulty, if not impossibility, of using RCTs to evaluate 
policy-level and health system interventions.2 3 With all 
types of non-RCT evidence starting off at a ‘low’ certainty 
level, public and global health researchers have voiced 
concerns that GRADE may inadvertently produce ratings 
that steer decision-makers away from implementing 
important system-level interventions.19–21 Concerns have 
also been raised on how to conceptualise the construct 
of ‘certainty’ in reviews of global health interventions, 
and consensus is currently lacking.3 Consequently, global 
health researchers could benefit from targeted guidance 
on how to rate certainty when encountering these chal-
lenges.2 3 9 21 22
objectives
As part of the overall series intended to stimulate 
thinking about how methods for reviewing and assessing 
evidence in guideline development can be enhanced 
to take account of complexity, this paper clarifies how 
a complexity perspective may be applied when using 
the GRADE approach to rate certainty of evidence. The 
GRADE Working Group is actively working to advance 
the GRADE methodology for different applications, 
including for diagnostic tests, prognostic studies and 
qualitative evidence.16 23 This paper focuses on using the 
GRADE approach for rating certainty in the evidence 
from systematic reviews estimating the effects of complex 
interventions and technologies in global health.
METHods
This paper is largely informed by an ongoing, mixed-
methods research project, GRADE Guidance for Complex 
Interventions, involving five key studies that follow an 
established methodology on developing guidance for 
health research.24 In Study 1, we investigated GRADE 
certainty ratings in 24 ‘complex’ and 16 ‘simple’ system-
atic reviews18 and obtained feedback from review authors 
on 19 of these reviews about their process of applying 
GRADE.2 In Study 2, we compared domains and criteria 
across GRADE and 16 other systems for rating certainty 
of evidence in health and social interventions.25 In 
Study 3, we interviewed 10 Cochrane review authors 
Table 1 Mapping the main sources of complexity onto difficulties in rating estimates of the effect of interventions (data taken 
from Movsisyan et al, 2016; Petticrew et al, 2013; Petticrew et al, 2019; Rehfuess and Akl, 2013)2 3 10 69
Source of complexity Difficulties in rating estimates of the effect of interventions
Multiple components  ► Interventions are comprised of different components, which may interact (synergistically or 
dysynergistically)
 ► Need to assess the effects of interventions as bundles or specific intervention components
Flexibility or tailoring or 
non-standardisation of 
implementation
 ► Ambiguities around how to assess fidelity to intervention implementation
Long causal pathways  ► Lack of direct evidence linking interventions with distal outcomes
 ► Need to integrate different pieces of evidence from potentially different bodies of evidence 
to estimate the distal effects
Effects are contingent on 
recipients’ and providers’ 
agency
 ► It may be impossible to blind recipients and providers of interventions
Multiple outcomes  ► Need to prioritise between a range of important (health and non-health) outcomes
Effects at different levels, 
for example, individual and 
population levels
 ► Need to consider outcomes at different levels (eg, individual, family and societal levels)
 ► Population-level interventions are frequently impossible to evaluate using RCTs, which 
results in downgrading the ‘best evidence possible’ for these interventions because of 
initial categorisation of evidence in GRADE based on study design
Moderating effects of context  ► Need to account for various implementation and contextual factors, when conceptualising 
and rating estimates of the effect
GRADE, Grading of Recommendations Assessment, Development and Evaluation; RCT, randomised controlled trial.
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and 5 GRADE methodologists on their views about the 
challenges of, and suggestions for, using GRADE in 
specific systematic reviews incorporating various sources 
and degrees of intervention and system complexity 
(Movsisyan et al, forthcoming). In Study 4, we conducted 
an online modified-Delphi process to explore areas of 
agreement and disagreement among 116 stakeholders 
about the importance of specific domains and criteria for 
rating certainty in systematic reviews of complex inter-
ventions (Grant et al, forthcoming). In Study 5, we held 
a 3-day consensus meeting to discuss proposals for the 
content of the new GRADE guidance for complex inter-
ventions with 28 stakeholders, purposively invited from 
the Delphi process, representing a range of subject areas 
(Movsisyan et al, forthcoming). All studies were approved 
by the Departmental Research Ethics Committee at the 
Department of Social Policy and Intervention, University 
of Oxford (SPI_C1A_16_009). This project draws sugges-
tions from several sources–including the existing GRADE 
guidelines and conceptual papers, previous work consid-
ering complexity in systematic reviews, HTAs and guide-
line development and consultation with relevant stake-
holders–to advise how to apply the GRADE approach 
using a complexity perspective in the context of global 
health.
rEsulTs
Several aspects of using GRADE require particular 
consideration when using a complexity perspective in 
systematic reviews and HTAs on the effects of inter-
ventions in global health (see table 1). Particularly 
important is that authors consider GRADE from the 
outset of the review or HTA and not at the end when 
evidence has already been synthesised. In this way, the 
totality of the evidence will become an integral part of 
the assessment from its inception. As systematic reviews 
represent an important source of evidence and are 
integral to most HTAs and guidelines in global health, 
below we describe how specific constructs and domains 
of GRADE can be used in systematic reviews using a 
complexity perspective.
Considering complexity and GrAdE when framing the 
question(s) and conducting the systematic review(s)
The certainty ratings at the final stage of the review are 
inextricably linked to the purpose and key questions 
established at the beginning of each complex inter-
vention review. Similar to the approach described in 
Petticrew et al, 201910, reviewers and guideline devel-
opers should identify sources and degrees of complexity 
inherent in interventions themselves, as well as the systems 
in which they are implemented and intended to influence 
(see table 1). As emphasised in the WHO-INTEGRATE 
framework (see Rehfuess et al, 201915), incorporation of 
sources of complexity into the review and, ultimately, into 
the GRADE ratings should be considered at the earliest 
stages of the review process: explicitly addressing sources 
of complexity when formulating review questions14 15 and 
structuring the proposed GRADE Evidence Profiles and 
Summary of Findings (SoFs) tables.26 Thinking through 
all relevant sources of heterogeneity at the beginning of 
the systematic review process will influence the types of 
data extracted and syntheses conducted. For instance, 
for a Cochrane review of environmental interventions to 
reduce the consumption of sugar-sweetened beverages 
and their adverse effects on health,27 reviewers developed 
a system-based logic model to guide data extraction, anal-
ysis and interpretation. The frameworks to extract and 
report relevant data were prespecified as were internal 
and external sources of heterogeneity for subgroup anal-
ysis (box 3). Such an approach is essential for capturing 
heterogeneity in the methodology and Population, Inter-
vention, Comparison, Outcome (PICO) elements, which 
would otherwise remain unexplained and almost inevi-
tably lead to downgrading of evidence.
A frequent challenge for authors of intervention 
reviews in global health arises from posing broad review 
questions on bundles of conceptually similar interven-
tions (often referred to as a ‘lumping’28 or a ‘holistic'29 
approach) that may actually have very different char-
acteristics.30 31 In these cases, authors should carefully 
consider upfront which sources of complexity are critical 
to include in their research questions, such as the active 
or ‘prototypical’ components of an intervention that are 
most likely to modify intervention effects.32
box 3 Consideration of sources of complexity in 
a protocol for a Cochrane review of environmental 
interventions to reduce consumption of sweetened 
beverages (von Philipsborn et al)27
von Philipsborn et al (2016) developed a system-based logic model 
taking into account:
 ► Beverage choices and diet-related health and non-health outcomes
 ► Physiological and psychological mechanisms linking sugar-sweet-
ened beverages with health outcomes at an individual level
 ► Interventions aimed at policy (macro) and settings (meso) and inter-
personal and intrapersonal factors (micro level)
 ► Determinants of diet-related outcomes and related interventions
This logic model was used to guide data extraction, analysis and 
interpretation.
Tools used for data collection:
 ► Template for Intervention Description and Replication framework to 
extract and report relevant data related to the intervention6
 ► Context and Implementation of Complex Interventions framework 
for contextual data63
Internal and external sources of heterogeneity were predefined at 
multiple levels, such as at policy or setting level:
 ► With or without behavioural cointerventions
 ► Targeted at: sugar-sweetened beverages, sugar-sweetened milk, 
beverages with non-nutritive sweeteners or beverages without 
added sweeteners
 ► Implemented in high-income, middle-income or low-income 
countries
 ► Targeted at the general population or at disadvantaged populations
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Logic models may be particularly helpful in depicting 
intervention components and identifying potential effect 
modifiers.10 11 32 33 A recent example involves a system-
atic review by Welch et al (2016) aiming to estimate 
the effects of deworming interventions on the develop-
mental health and well-being outcomes of children in 
LMICs.34 While evidence for deworming programmes 
had been debated,35–37 review authors made considerable 
efforts to describe the complexities of the programme. 
Specifically, they developed a logic model at the outset 
of the review to elucidate the entire causal chain from 
worm infection to nutritional status and educational 
outcomes, how deworming–in combination with other 
strategies (such as hygiene promotion and sanitation)–
intervenes in the pathway and which factors might be 
important in mediating or moderating the effects (such 
as poverty, prevalence and intensity of infection and spill-
over effects).34 This complexity perspective allowed them 
to add important questions to their overall question of 
‘what works’, such as the effects of deworming according 
to the prevalence of infections, as well as the synergistic 
effects of cointerventions and treatment externalities for 
untreated children. They then constructed three separate 
GRADE SoF tables to provide certainty ratings depending 
on the levels of endemicity for which different strategies 
of mass deworming were relevant.34
defining the thresholds or the ranges for certainty of evidence 
ratings
The GRADE Working Group conceptualises ‘certainty of 
evidence’ as confidence that the true effect of an inter-
vention lies on one side of a specified threshold or within 
a chosen range (see table 2).38 In general, depending 
on the purpose of the assessment (ie, whether the 
systematic review informs a guideline or not), certainty 
of evidence ratings are presented as ‘non-contextual-
ised’, ‘partly contextualised’ and ‘fully contextualised’. 
Non-contextualised ratings are relevant for assessments 
conducted outside of a guideline (eg, Cochrane and 
Campbell reviews): in these circumstances, authors may 
prioritise the threshold of the null effect and conceptu-
alise certainty of evidence as confidence that a non-null 
effect is present, that is to say, that the effect of one inter-
vention differs from another. Alternatively, the range 
approach may be chosen, and certainty of evidence 
may be conceptualised as confidence that the effect 
lies within a given range (eg, a 95% CI or prediction 
interval). Finally, authors may instead choose a partly 
contextualised rating, setting thresholds of specified 
magnitudes of effect (eg, what may be considered as a 
trivial, small, moderate or large effect). Fully contextu-
alised ratings are relevant when systematic reviews are 
conducted as part of a specific guideline development 
or decision-making process, which enables integration 
of other considerations relevant for a health decision. In 
this case, authors could rate the certainty that the effect 
lies above a threshold that makes implementation of the 
intervention worthwhile.38
The non-null effect is likely the simplest and most 
feasible threshold for rating certainty on the effects of 
public health interventions. Since these intervention 
effects may vary depending on implementation factors, 
context and settings, it may be very challenging for a 
review group to define specific magnitudes of effect for 
various outcomes that are practically important for all 
potential contexts of application. Rating certainty in the 
non-null effect would inform the broad global reader-
ship about the general direction (positive or negative) 
of an intervention effect. The task will then be left for 
Table 2 Approaches for setting thresholds or ranges for certainty of evidence ratings (adapted from Hultcrantz et al, 2017)38
Setting Contextualisation Threshold or range How to set
What certainty rating 
represents
Primarily for systematic 
reviews and health 
technology assessment
Non-
contextualised
Range: 95% CI Using existing limits of the 
95% CI, which implies that 
precision is not routinely 
part of the rating
Certainty that the effect lies 
within the CI
OR≠1; RR≠1; HR≠1; 
RD≠0
Using the threshold of null 
effect
Certainty that the effect of 
one treatment differs from 
another
Primarily for systematic 
reviews and health 
technology assessment
Partly 
contextualised
Specified magnitude 
of effect
For example, small effect 
is the effect small enough 
to not use the intervention 
if adverse effects/costs are 
appreciable
Certainty in a specified 
magnitude of effect for one 
outcome (eg, trivial, small, 
moderate or large)
Primarily for practice 
guidelines
Fully 
contextualised
Threshold 
determined with 
consideration of all 
critical outcomes
Considering the range 
of effects on all critical 
outcomes, and the values 
& preferences for those 
ranges 
Confidence that the direction 
of the net effect will not differ 
from one end of the certainty 
range to the other
RD, risk difference; RR, risk ratio.
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the end-users of the evidence at the local level to further 
contextualise the evidence and set the corresponding 
thresholds informing implementation of the interven-
tion depending on their specific circumstances. Impor-
tantly, contextualising the evidence usually involves a 
broad range of considerations and decisions not solely 
driven by evidence of intervention effectiveness.15
The choice of the thresholds or ranges will have impli-
cations for how the domains of the GRADE approach are 
applied in a given review or guideline. For example, the 
criteria of imprecision and inconsistency are only margin-
ally relevant when assessing certainty in the non-null 
effect (as long as there is consistency in the direction 
of effect across studies), but are highly relevant when 
assessing certainty in a specified magnitude of effect. It is 
therefore critical for systematic reviewers and guideline 
developers to make their choice explicit and to carry it 
through into rating the evidence (see table 3 for further 
details).
Initial certainty rating based on study design
Following definitions of review scope and thresholds or 
ranges for rating the certainty of evidence, the initial 
rating is based on study design. Given the practical 
impossibilities of conducting RCTs for many complex 
interventions, global health researchers have struggled 
with the convention that a body of RCTs is initially 
rated as ‘high’ certainty in the GRADE approach and 
a body of NRSs as ‘low’ certainty.2 3 39 Moreover, there 
are clearly differences with respect to one’s ability to 
draw causal inferences about intervention effects from 
a cross-sectional study, a very weak design for that 
aim, compared with a much stronger design, such as 
controlled interrupted-time series; however, both study 
designs would start off as ‘low’ certainty in GRADE.
Partly in response to these concerns, the GRADE 
Working Group has recently suggested a second 
approach, in which any body of evidence may receive 
a ‘high’ initial certainty rating provided that a rigorous 
tool has been used to assess risk of bias.40 The new risk 
of bias in non-randomised studies (ROBINS-I) tool for 
cohort-type studies is the only tool recognised by the 
GRADE Working Group as meeting this standard for 
NRSs.40 41 Compared with other tools, ROBINS-I offers 
a rigorous process for assessing risk of bias through 
seven distinct domains and overall 34 signalling ques-
tions, but requires both significant human resources 
and substantial epidemiological expertise.41 42 This 
nuanced assessment of risk of bias in ROBINS-I, specifi-
cally, regarding the domains of confounding and selec-
tion bias, allows for RCTs and NRSs to be placed on a 
common metric for risk of bias. While this approach 
enables one to initially rate evidence from NRS designs 
as ‘high’ certainty, it is expected that the certainty of 
evidence will eventually be downgraded for risk of bias, 
so that the final rating is the same no matter the starting 
point (ie, whether a body of evidence from NRSs was 
initially rated as ‘low’ certainty and subsequently rated 
up or down or whether it was initially rated as ‘high’ 
certainty and further downgraded). It is important to 
note that the current version of ROBINS-I is primarily 
designed for cohort studies. Although future initiatives 
may develop extensions to ROBINS-I for other types of 
NRS designs, following the original GRADE guidance 
for initial rating of evidence based on study design, the 
body of evidence comprised of NRSs other than cohort 
studies should be initially rated as ‘low’ certainty.40 43 
Authors should then explain their decisions for further 
downgrading or upgrading of the certainty of evidence 
(eg, subsequent downgrading the certainty of a body 
of evidence from cross-sectional studies for additional 
concerns over the risk of bias).
Applying GrAdE domains for rating certainty
We further highlight how reviewers and guideline devel-
opers in global health may address sources of complexity 
when making judgements on specific domains of the 
GRADE approach.
Risk of bias
Handling performance bias in certainty ratings has proven 
challenging in reviews of interventions, where it is often 
impossible to blind participants and/or providers.44 45 A 
common source of complexity is the contingency of inter-
vention effects on recipients’ and providers’ agency.46 
The challenge therefore is to assess if the lack of blinding 
introduces a risk of bias that implies reduced confidence 
in the effect estimates. To do so, review authors should 
be careful to differentiate between ‘lack of blinding’ 
and the judgement for the potential of ‘performance 
bias’ typically associated with the lack of blinding.47 
Lack of blinding does not always cause sufficient bias 
to warrant downgrading for risk of bias. Indeed, lack of 
blinding may be an essential aspect of the intervention 
of interest, particularly when knowledge of the presence 
of the intervention is an important aspect of its effec-
tiveness as in a traffic safety enforcement campaign. In 
these circumstances, other considerations become even 
more important, such as blinding of outcome assessors 
or the nature of the comparator.48 For example, for the 
outcome ‘quality of life’, authors conducting a review on 
rehabilitation for chronic obstructive pulmonary disease 
did not downgrade for lack of blinding of provider and 
participants because they judged the procedures used in 
included studies to blind outcome assessors sufficient to 
address any concerns about risk of bias.49 Furthermore, 
the potential for bias due to lack of blinding will also 
depend on the PICO question of the review.48 Subjec-
tive outcomes are more prone to bias than objectively 
measured outcomes, such as all-cause mortality. Lack of 
blinding would be a more important source of bias when 
the comparator in the review is ‘usual care’ than an active 
intervention, such as when comparing two different 
educational interventions.
It is worth noting that assessment of performance 
bias has been revised in the new Cochrane tool to assess 
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Table 3 Key considerations for rating certainty in systematic reviews on the effects of complex interventions
Recommendation Rationale
Deciding on the scope of the review
  1. Use logic models to develop 
PICO and review questions
 ► Logic models help in scoping, defining and conducting the review and in making the review relevant to 
policy and practice. Approaches have been developed to assist with this10 33 58 70
  2. Identify which tools to use 
to best describe the sources of 
complexity that users will require
 ► There are several newly developed tools on using a complexity perspective in systematic reviews, 
such as the approach by Petticrew et al 2019,10 iCAT_SR, the CICI framework, TIDieR and PRISMA-
CI6 63 65 66
  3. Using these tools identify 
contextual and implementation 
factors and other moderators 
of effect that may help explain 
heterogeneity and which will 
need separate GRADE certainty 
ratings
 ► In addition to the standard PICO question, identify in both the intervention and the system in which it 
is being used all the complexities and interactions that review users will want to know about10
 ► Under intervention complexities, consider aspects of its implementation, such as theory of why and 
how the intervention is expected to work, the components, implementers, mediators, moderators, and 
causal pathways 
 ► Under system complexities, consider context, setting and any other independent interventions taking 
place
Defining thresholds or ranges for certainty of evidence ratings
  Define ‘certainty’ in a manner 
that matches the needs of the 
intended users of the review
 ► Decide among the three approaches to defining certainty of evidence: ‘non-contextualised’, ‘partly 
contextualised’ and ‘fully contextualised'38
 ► In each case, specify the threshold or ranges used to rate certainty of evidence
 ► For ‘non-contextualised’ reviews, consider the utility of using GRADE for the ‘non-null’ effect
  3. Using these tools identify 
contextual and implementation 
factors and other moderators 
of effect that may help explain 
heterogeneity and which will 
need separate GRADE certainty 
ratings
 ► In addition to the standard PICO question, identify in both the intervention and the system in which it 
is being used all the complexities and interactions that review users will want to know about10 .
 ► Under intervention complexities, consider all aspects of its implementation, including theory of 
why and how the intervention is expected to work, the process, the components, implementers, 
moderators, causal pathways (linear and non-linear) and important process outcomes
 ► Under system complexities, consider context, setting (eg, individual or population level) and any other 
independent interventions taking place
Rating certainty of evidence using GRADE
  1. Initially rate any body of 
evidence as ‘high’ if a rigorous 
tool is used to assess risk of 
bias in NRSs (ie, ROBINS-I), 
otherwise, use the ‘standard’ 
GRADE guidance
 ► Consider using Cochrane Risk of Bias (RoB V.2.0) tool for randomised controlled trials42
 ► Consider using ROBINS-I for cohort-type studies41
  2. Give extra scrutiny to the 
impact of lack of blinding 
providers/participants on overall 
risk of bias for outcomes
 ► If lack of blinding of either participants of providers is unlikely to affect assessment of outcome (such 
as when using objective outcome measures, for example, mortality), then consider not downgrading 
evidence for lack of blinding for that outcome.
  3. Consider the effect of bias 
associated with deviation from 
the intended intervention
 ► Deviations, such as poor adherence, poor implementation and cointerventions in relation to the effect 
of starting and adhering to an intervention, may lead to bias and may be downgraded by one level
 ► Consider not downgrading if assessing the effect of assignment to the intervention, when deviations 
do not occur in relation to usual practice and groups remain balanced
  4. Consider multiple criteria 
for judging inconsistency of 
evidence
Assessment of heterogeneity should always start off with an appraisal of study heterogeneity, including 
heterogeneity in PICO elements as well as methodological aspects
 ► Assessment of heterogeneity should take account of multiple rather than single criteria for 
inconsistency (eg, I2 and its p value, overlap of CIs and degree of variation within chosen thresholds)
 ► Consider whether definition of certainty of evidence influences nature of inconsistency assessment 
(eg, when effect sizes across all studies are consistently in the same direction outside of the null effect 
or a given threshold of interest, then downgrading for inconsistency is not warranted despite other 
measures)
 ► Consider different analytical methods to explain heterogeneity (eg, subgroup analysis, meta-
regression and qualitative comparative analysis)
  5. Rate imprecision of evidence 
with regard to the adopted 
definition of ‘certainty’
 ► Consider whether definition of certainty of evidence influences nature of imprecision assessment38
 ► For ‘non-contextualised’ systematic reviews definition, a certainty that the effect lies within estimated 
CIs or prediction intervals, a GRADE assessment for imprecision can usually be omitted as 
assessment of precision is dependent on the chosen range
 ► For ‘partly contextualised’ systematic reviews, consider whether the point estimate would represent a 
trivial, small, moderate or large absolute effect
 ► For ‘fully contextualised’ systematic reviews, simultaneously consider all important outcomes to 
determine precision of the effect estimate
Continued
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risk of bias in randomised trials (RoB V.2.0)42 and in 
ROBINS-I.41 In this revised version of the RoB tool, 
performance bias is assessed under the domain of ‘bias 
due to deviations from intended interventions’, which 
allows for assessing two different aims of the trial: either 
the effect of assignment to intervention or the effect of 
starting and adhering to intervention. When interest is 
in the effect of assignment to intervention (also known 
as ‘treatment offer’), lack of blinding of intervention 
recipients and providers may not warrant downgrading 
certainty of evidence, as the deviations from the intended 
intervention should not create a prognostic unbalance 
between the trial groups. However, in relation to starting 
and adhering to the intervention, deviations, such as 
poor adherence, poor implementation and cointerven-
tions, may lead to risk of bias.42 Many interventions in 
global health, such as educational and behaviour change 
interventions, require tailoring to specific contexts. 
Accordingly, authors should exercise judgement on the 
level of differences in intervention implementation that 
are beyond what would otherwise be expected in a real-
world context.
Inconsistency
Interventions examined in global health reviews often 
vary in how they are implemented in different contexts 
and in outcome measures used across settings.3 18 Conse-
quently, reviews often find considerable heterogeneity 
in effect estimates. The proper consideration of sources 
of complexity when framing the review questions can 
facilitate assessments of whether to downgrade for incon-
sistency at this later stage of the review. Namely, review 
authors can group and synthesise the included studies 
according to the nature of relevant sources of complexity 
and, if these sources of complexity help explain heter-
ogeneity, provide separate certainty ratings for each of 
these groupings.32 50
Judgements of inconsistency in the magnitude or 
direction of effects should correspond with the chosen 
threshold or range that the review team adopts for rating 
certainty of evidence. For example, if the review team 
chooses the null effect as a threshold for rating certainty 
in the estimate of effect, then judging inconsistency in the 
direction of effect (ie, beneficial or harmful) would be a 
relevant approach to follow. In this case, variation in point 
estimates and statistically significant heterogeneity may 
not warrant downgrading for inconsistency if the effects 
across studies are consistently in the same direction with 
respect to the null effect.50 51 However, if reviewers are 
rating their certainty in whether the average effect lies 
within an estimated range, such as within the CIs, then 
authors should consider multiple criteria for inconsis-
tency (eg, overlap of CIs, degree of variation with respect 
to chosen thresholds and I2 and its p value), rather than 
using only a single statistical measure of heterogeneity.50
Imprecision
Judgements for imprecision are contingent on reviewers’ 
chosen thresholds for rating certainty. If the chosen 
threshold is the null effect, then imprecision will not 
be a concern to warrant downgrading evidence unless 
the confidence or prediction interval includes the null 
effect, in which case the evidence is either (1) imprecise 
(due to small number of events or participants) or (2) 
precise and the intervention does not have an effect rela-
tive to the comparator.38 For the latter, the confidence 
or prediction interval needs to be sufficiently narrow 
around the null effect to exclude a ‘meaningful’ effect 
established a priori.38 If clearly stated, authors rating 
certainty of effects within 95% CIs may omit a precision 
assessment.38 This approach, however, has not yet been 
used in any review and needs further testing on examples 
using complex health interventions (Montgomery et al, 
forthcoming).
Recommendation Rationale
  6. Examine indirectness of 
evidence by way of assessing 
important differences in the 
evidence base beyond what is 
expected
 ► Consider grouping studies, synthesising evidence and rating certainty in the estimates of effect for 
separate outcomes according to the relevant sources of complexity identified at the start of the review
 ► Consider splitting the questions to answer subset conditions, downgrading only for those with less 
certain evidence. Do not downgrade for indirectness if observed differences are unlikely to affect the 
outcome
  7. Consider publication bias  ► Conduct extensive grey literature searches and expert contacts to identify reports and working papers
 ► Consider sponsorship of studies by any vested industries as well as potential ‘allegiance bias’
  8. Upgrading evidence  ► Consider upgrading certainty of evidence for a dose–response relationship related to the level of 
implementation
 ► Consider upgrading evidence for a body of evidence from studies with low implementation fidelity 
positive results which counteract plausible residual bias or confounding
  Use logic models to investigate 
coherence of evidence across 
the causal pathway
 ► Consider assessing the coherence of evidence across different links in the causal pathway at the end 
of evidence synthesis. This judgement should be made outside of the GRADE framework
CICI, Context and Implementation of Complex Interventions; GRADE, Grading of Recommendations Assessment, Development and 
Evaluation; iCAT-SR, Intervention Complexity Assessment Tool for Systematic Reviews; NRS, non-randomised study; PICO, Population, 
Intervention, Comparison, Outcome; PRISMA-CI, Preferred Reporting Items for Complex Interventions for Systematic Reviews and Meta-
analyses; ROBINS-I, risk of bias in non-randomised studies; TIDieR, Template for Intervention Description and Replication.
Table 3 Continued 
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Indirectness
Many of the reported challenges of judging indirect-
ness can be addressed by specifying appropriate review 
questions. Important differences in the PICO elements 
beyond what is expected and specified in the review may 
weaken inferences regarding the directness of evidence. 
As outlined in the original GRADE guidance on indirect-
ness, “it is however rare and usually unnecessary, for the 
intended populations and interventions to be identical to 
those in the studies, and evidence should be downgraded 
only if the differences are considered sufficient to make a 
difference in the outcome likely”.52
Another potential challenge relates to incompleteness 
of available evidence with regard to the review question. 
As questions for the global health audience might neces-
sarily be broad (ie, often follow a ‘lumping’ approach), 
the available evidence might not address all elements 
in the PICO framework (eg, while the question may 
ask for evidence in both LMICs and high-income coun-
tries, the evidence may only be available for high-in-
come countries). If authors suspect major differences in 
effect across the locations, rather than downgrading all 
evidence for indirectness, an alternative approach is to 
split the question to be able to provide direct evidence 
for a subset of conditions (eg, make separate certainty of 
evidence ratings for LMICs and high-income countries). 
In this case, authors may report a lack of evidence for the 
remaining subset of conditions (eg, LMICs) or extrapo-
late based on available data. In the latter case, however, 
reviewers may need to downgrade evidence for indirect-
ness. Again, it is highly recommended that reviewers think 
about the factors that may modify intervention effects at 
the beginning of the review process, when scoping the 
review and formulating specific questions.
Publication bias
Many evaluations of global health interventions are 
published as reports, working papers or programme eval-
uations. If review authors suspect that eligible studies are 
likely published in this format (rather than in indexed 
scientific literature), a comprehensive multicompo-
nent search that includes grey literature and contacting 
of experts is critical. In addition, authors should assess 
whether a substantial number of studies are sponsored 
by any vested industries (eg, intervention developers and 
representatives from industries benefiting from the status 
quo) or run by researchers with a potential ‘allegiance 
bias’ to warrant downgrading for publication bias.53
Upgrading
The criteria for upgrading evidence of complex interven-
tions should follow the guidance of the GRADE Working 
Group,54 including guidance on upgrading when all types 
of study design are initially rated at ‘high’ certainty.40 
In line with the GRADE guidance, upgrading criteria 
commonly apply when there are no major limitations in 
the body of evidence (such as risk of bias, inconsistency 
or imprecision).54 One special case for complex interven-
tions involves intervention fidelity: authors may upgrade 
their certainty rating if (1) larger effects are found in 
studies with better implementation (criterion of dose–
response effect) or (2) positive results are found among 
studies with low implementation fidelity (counteracting 
plausible residual confounding).
Future work for rating certainty in reviews using a complexity 
perspective
Based on our project findings, we suggest several areas of 
future work. Many interventions and complex technol-
ogies may have long and variable causal pathways. Our 
consultation with stakeholders suggests a strong interest 
in developing a robust domain for an approach to rating 
certainty that is based on the ‘coherence of the causal 
pathway’ or ‘chain of evidence’.55 56 A similar approach 
is currently used by the US Preventive Services Task 
Force to describe different links in the causal chain of an 
intervention and inform what types of evidence should 
be searched for and synthesised (figure 1).57 If review 
authors manage to populate different links in the causal 
chain of an intervention with rigorous evidence (eg, links 
4 and 7 in figure 1), then this may increase their certainty 
in the effects of its distal outcomes (eg, link 5 in figure 1). 
As discussed in the previous example on deworming 
interventions, logic models (also known as analytical 
frameworks) that visually depict the links in these causal 
pathways can be useful in identifying the important items 
of evidence that should be searched for and synthesised 
in a systematic review.33 Authors could revisit their initial 
logic models at predefined stages of the review process, 
in particular, at the end of the review, using the evidence 
collected and synthesised for each individual link in 
the pathway, to assess coherence in the causal pathway 
originally proposed.58 This chain of evidence approach 
might be particularly informative in circumstances where 
direct evidence linking the intervention with the distal 
outcomes is unavailable. The work is ongoing both within 
the GRADE Working Group and beyond, for example, 
on how to conduct model-driven synthesis of evidence.59
Second, several stakeholders are interested in more 
systematically examining whether there are specific NRS 
designs that are consistently sufficiently robust to start as 
‘moderate’ rather than ‘low’ certainty in the traditional 
GRADE approach. Such an approach would allow for a 
‘quick and dirty’ sorting of study designs, where stronger 
NRS designs would start off as ‘moderate’ certainty and 
weaker designs as ‘low’ certainty. Advantages would be 
a quicker and more user-friendly distinction between 
different levels of certainty, which is likely to be appli-
cable by many Cochrane and non-Cochrane systematic 
reviewers; the initial rating could then be refined by 
risk of bias assessments, but would be less dependent on 
the use of a very sophisticated risk of bias tool, such as 
the ROBINS-I tool. The significant challenge, however, 
relates to which study designs and associated features 
merit starting in one category versus the other.60 61 Based 
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on the results of our Delphi process and the consensus 
meeting, this option was generally supported by those 
concerned with inconsistent implementation of NRS 
risk of bias tools leading to overestimation of certainty, 
especially given the novelty of the tools and varying levels 
of expertise in using them.62 However, we do not recom-
mend this approach until future research conclusively 
establishes such a set of acceptable NRS designs.
ConClusIon
This primer provides a concise discussion of how to 
incorporate a complexity perspective when applying 
the GRADE approach in systematic reviews estimating 
the effects of interventions in global health. Key consid-
erations include: sources of complexity when framing 
the review questions, such as important dimensions of 
context and implementation and other potential media-
tors and moderators of effect; a choice of a threshold or 
a range that matches the needs of intended users of their 
review, assessment of evidence from NRS designs and the 
criteria within each GRADE domain for rating certainty 
(see table 3). Suggested future work involves investi-
gating the feasibility of (1) a domain on the coherence 
of evidence across the hypothesised causal pathway of an 
intervention, which may not need to be integrated into 
the GRADE ratings as it will apply at a higher, systematic 
review level beyond assessment of certainty of evidence 
in specific outcomes and (2) the identification of 
specific NRS designs that could start as ‘moderate’ rather 
than ‘low’ certainty. Researchers, including systematic 
reviewers, authors of HTA and guideline developers in 
global health should continue to report their experi-
ence using GRADE and this primer in reviews aiming to 
address sources of complexity. More examples of using 
GRADE are particularly needed for social interventions, 
interventions in LMIC contexts, assessments where 
meta-analysis may not be possible, in bodies of evidence 
with rigorous NRSs (as well as mixed bodies of evidence), 
and by researchers with varying degrees of experience in 
systematic reviewing and evidence assessment.
There is wide interest in finding ways to assess which 
interventions are effective and, equally, which ones are 
relevant and appropriate in diverse contexts. Using 
a complexity perspective can contribute to this. This 
discussion on considering the ‘complexity perspective’ in 
GRADE ratings provides a primer for systematic reviewers, 
authors of HTA and guideline developers to better assess 
evidence relating to complex interventions and systems, 
which could ultimately enhance the use of such evidence 
in global health policy and practice decisions.
Figure 1 Example chain of evidence approach: screening and interventions for overweight in childhood. Arrow 1: Is there 
direct evidence that screening (and intervention) for overweight in childhood improves age-appropriate behavioural or 
physiological measures or health outcomes? Arrow 2: (1) What are appropriate standards for overweight in childhood, and 
what is prevalence of overweight based on these? (2) What clinical screening tests for overweight in childhood are reliable 
and valid in predicting obesity in childhood? (3) What clinical screening tests for overweight in childhood are reliable and valid 
in predicting poor health outcomes in adulthood? Arrow 3: What are the adverse effects of screening, including labelling? Is 
screening acceptable to patients? Arrow 4: (1) Do weight control interventions lead to improved intermediate outcomes? (2) 
What are common behavioural and health system elements of efficacious interventions? (3) Are there differences in efficacy 
between patient subgroups? Arrow 5: Do weight control interventions lead to improved health outcome and/or improved 
functioning? Arrow 6: What are the adverse effects of interventions? Are interventions acceptable to patients? Arrow 7: 
Are improvements in intermediate outcomes associated with improved health outcomes? (Only evaluated if there is no 
direct evidence for link 1 or link 5 and if there is sufficient evidence for link 4). BMI, body mass index. Taken from Whitlock 
et al, 2005.57
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